Navigation Links
Pipeline for Breast Cancer Therapies is Focus of New MedPredict Report
Date:8/27/2008

SCOTTSDALE, Ariz., Aug. 27 /PRNewswire/ -- MedPredict has published a new report in its oncology series entitled "Thought Leader Insight & Analysis: Breast Cancer," designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for diagnostics and treatments in this disease area. MedPredict interviewed renowned North American and European breast cancer thought leaders to identify the most promising candidates in clinical development, as well as explore unmet needs. They address the following questions:

-- Has Novartis jumped ahead of Amgen in developing a breast cancer drug that provides a mortality benefit and preserves bone? MedPredict's panel debates the implications of Novartis' positive zoledronic acid (Zometa) data presented at ASCO 2008.

-- How prevalent is osteonecrosis of the jaw with antiresorptives, and how will this affect their usage in breast cancer?

-- How is triple negative breast cancer being treated, and where are the opportunities for development in this subtype?

-- What are the best approaches for development of inhibitors of mTOR, IGF1R, EGFR, PARP-1, HSP90, Src, angiogenesis, FA2, hedgehog, and vaccines?

"This report will provide essential strategic insight for those involved in development of breast cancer therapies," according to MedPredict President Dr. Jeffrey Berk. "Our report discusses ongoing clinical programs, and offers insight into which of the many new drugs in development are likely to be significant improvements over current options."

Companies included in this report: Abbott (ABT-888, ABT-999, A-928605), Abraxis/AstraZeneca (Abraxane), Amgen (denosumab, AMG-479), AstraZeneca (Arimidex, olaparib, saracatinib), Bayer-Schering (Bonefos), BiPar (BSI-201, BSI-401), Boehringer Ingelheim (Tovok), Bristol-Myers Squibb (brivanib, BMS-754807, Sprycel, Ixempra), BMS/Imclone (Erbitux), Exelixis (XL-765, XL-647), Genentech (Avastin, GDC-0941, Herceptin, pertuzumab, trastuzumab-DM1), GlaxoSmithKline (Tykerb), Imclone (IMC-A12, IMC-1121B), Kosan (tanespimycin), Merck (Fosamax, odanacatib, MK-0646), Myriad (BRCA1/BRCA2 Screening), Merck/Ariad (deforolimus), Novartis (Zometa, Femara, everolimus, patupilone, TAE-266), OSI (OSI-906), Pfizer (Aromasin, Sutent, Tarceva, CP-751871), Pierre Fabre (Javlor), Roche/GSK (Boniva), Roche (Xeloda), Sanofi-Aventis (AVE-1642), Schering-Plough (SCH-717454), and Wyeth (Torisel, neratinib).

The full report can be purchased by contacting MedPredict.

About MedPredict

MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders. Based on primary interviews with these thought leaders, MedPredict publishes periodic therapeutic area reports to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and presentations, as well as clinical, regulatory and marketing activity.


'/>"/>
SOURCE MedPredict
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. The Michigan Life Sciences Pipeline Adds More Resources On Its Website
2. Alexza to Announce 2008 Second Quarter Financial Results and Update Its Clinical Pipeline on Wednesday, August 6, 2008
3. SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update
4. BioMS Medical Provides Update On Pipeline Products
5. SGX Pharmaceuticals Schedules Teleconference and Webcast to Discuss First Quarter 2008 Results and Provide Pipeline Update
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
7. Abbott Annual Meeting Highlights Outstanding 2007 Results, International Growth and Near-Term Pipeline
8. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
9. Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
10. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
11. Pipeline for Lung Cancer Therapies is Focus of New MedPredict Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... CA (PRWEB) , ... June 23, 2016 , ... ... software, is exhibiting at the Pennsylvania Convention Center and will showcase its product’s ... conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical Trials ...
(Date:6/23/2016)...  Amgen (NASDAQ: AMGN ) today announced ... life sciences incubator to accelerate the development of new ... at QB3@953 was created to help high-potential life science ... early stage organizations - access to laboratory infrastructure. ... two "Amgen Golden Ticket" awards, providing each winner with ...
(Date:6/22/2016)... , June 22, 2016 Research and ... Global Markets" report to their offering. ... billion in 2014 from $29.3 billion in 2013. The market is ... of 13.8% from 2015 to 2020, increasing from $50.6 billion in ... projected product forecasts during the forecast period (2015 to 2020) are ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
(Date:4/13/2016)...  IMPOWER physicians supporting Medicaid patients in ... standard in telehealth thanks to a new partnership with ... IMPOWER patients can routinely track key health measurements, such ... and, when they opt in, share them with IMPOWER ... local retail location at no cost. By leveraging this ...
Breaking Biology News(10 mins):